Sorriso Pharmaceuticals is a biotech firm developing disease-modifying antibodies for the treatment of inflammatory diseases.
Sorriso Pharmaceuticals has raised $31.0M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Sorriso Pharmaceuticals's investors include New Enterprise Associates, Arix Bioscience.
Sorriso Pharmaceuticals is headquartered in San Diego, United States.
Sorriso Pharmaceuticals is a biotech firm developing disease-modifying antibodies for the treatment of inflammatory diseases.
Sorriso Pharmaceuticals is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sorriso Pharmaceuticals — Funding & Investors." VCBacked, December 22, 2021, https://www.vcbacked.co/company/sorriso-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2021). Sorriso Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/sorriso-pharmaceuticals
{{cite web |title=Sorriso Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/sorriso-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated